HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir AB (STO:MVIRB)
Financial summary
Fourth quarter 2015 (2014)
· Net turnover totalled SEK 84.7 million (377.0 m), SEK 31.1 million (220.1 m) of which comprised royalties for simeprevir.
· Revenues from Medivir’s own pharmaceutical sales totalled SEK 53.1 million (156.6 m), of which SEK 2.7 million (103.1 m) derived from sales of OLYSIO® and SEK 50.4 million (53.5 m) from sales of other pharmaceuticals.
